Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

NCT06999187 is registered in ClinicalTrials.gov with Dren Bio as lead sponsor.

NCT NCT06999187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06999187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Lead sponsor
Dren Bio
Phase
Phase 1
Overall status
Recruiting
Start date
June 3, 2025
Completion date
December 31, 2027
Enrollment
96 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, cervical cancer, endometrial cancer, gastric cancer, gastroesophageal-junction cancer, head-and-neck squamous cell carcinoma, her2-negative breast cancer, non small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer, urothelial carcinoma